

**Listing of Claims:**

1.-8. (Canceled)

9. (Currently Amended)      A method for producing human Tr1-like regulatory cells which comprises:

(i)      activating CD4<sup>+</sup> CD25<sup>+</sup> T cells to produce activated CD4<sup>+</sup> CD25<sup>+</sup> T cells by subjecting unactivated CD4<sup>+</sup> CD25<sup>+</sup> T cells to an activation stimulus consisting of at least one of: (a) plate-bound anti-CD3 and soluble anti-CD28 antibodies; ~~or~~ and (b) mature dendritic cells;

(ii)      anergizing CD4<sup>+</sup> CD25<sup>-</sup> T cells by contacting the CD4<sup>+</sup> CD25<sup>-</sup> T cells *ex vivo* with an anergic state inducing agent consisting of said activated CD4<sup>+</sup> CD25<sup>+</sup> T cells and said activation stimulus to yield human Tr1-like regulatory cells.

10. (Canceled)

11. (Previously Presented)      The method of claim 9, wherein said contacting comprises coculturing the CD4<sup>+</sup> CD25<sup>-</sup> T cells with the CD4<sup>+</sup> CD25<sup>+</sup> T cells.

12.-28. (Canceled)

29. (Previously Presented)      The method of claim 9, wherein said Tr1-like regulatory cells produce IL-10.

30. (Previously Presented) The method of claim 29, wherein said Tr1-like regulatory cells suppress the proliferation of syngeneic CD4<sup>+</sup> T cells.

31.- 38. (Canceled)